Covid-19 roundup: Pfiz­er, BioN­Tech kick off EUA dance for teen bi­va­lent shot; Re­port de­tails slow US boost­er roll­out

While Mod­er­na’s vac­cine has been sent off for an EUA for teens and pre­teens, its ri­vals, Pfiz­er and BioN­Tech, are right on its heels with an EUA sub­mis­sion of their own.

On Mon­day, both com­pa­nies an­nounced that they fin­ished sub­mit­ting an EUA to the FDA for the bi­va­lent boost­er for chil­dren aged five through 11 to counter the Omi­cron BA.4/BA.5 strains of Covid-19. Both com­pa­nies have al­so start­ed a “Phase I/II/III study” to eval­u­ate the safe­ty and tol­er­a­bil­i­ty of dif­fer­ent dos­ing reg­i­mens for the boost­er in chil­dren from six months to 11 years old.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.